Highlights NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-16 pm EST			5-day change	1st Jan Change
12.93 ^USD	-0.31%		+1.81%	-56.61%

Dec. 01	Novocure Limited Announces CEO Changes	CI
Dec. 01	Novocure appoints company president Frank Leonard as chief executive officer	RE

Highlights

NovoCure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	Oct. 30	CI
NovoCure Q3 Net Loss Widens, Revenue Rises	Oct. 30	MT
Novocure Q3 revenue beats estimates	Oct. 30	RE
Earnings Flash (NVCR) Novocure Limited Reports Q3 Revenue $167.20M, vs. FactSet Est of $158.9M	Oct. 30	MT
Novocure to report third quarter 2025 financial results	Oct. 01	RE
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of Its Tumor Treating Fields Therapy for Brain Metastases from Non-Small Cell Lung Cancer At 2025 ASTRO Annual Meeting	Sep. 29	CI
Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer	Sep. 15	CI
NovoCure's Optune Lua Receives Approval in Japan to Treat Certain Non-Small Cell Lung Cancer Patients	Sep. 15	MT
Novocure Announces Coverage of Tumor Treating Fields Therapy for Patients with Newly Diagnosed Glioblastoma in Spain	Aug. 25	CI
NovoCure's TTFields Now Covered by Spanish National Health System	Aug. 25	MT
NovoCure Limited Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer	Aug. 20	CI
NovoCure Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	Jul. 24	CI
NovoCure's Q2 Net Loss Widens, Revenue Rises	Jul. 24	MT
Novocure Q2 revenue up 6%, beats analyst estimates	Jul. 24	RE
Earnings Flash (NVCR) Novocure Posts Q2 Loss $0.36 a Share, vs. FactSet Est of $0.38 Loss	Jul. 24	MT
Earnings Flash (NVCR) Novocure Limited Reports Q2 Revenue $158.8M, vs. FactSet Est of $154.2M	Jul. 24	MT
Novocure to Present Final Secondary Endpoint Data from the Phase 3 Panova-3 Trial of Tumor Treating Fields in Pancreatic Cancer At the Esmo Gastrointestinal Cancers Congress 2025	Jul. 01	CI
Zai Lab and Novocure Announce Results from the Phase 3 Panova-3 Trial of Tumor Treating Fields Therapy for Pancreatic Cancer to Be Presented At 2025 Asco Annual Meeting	May. 31	CI
Novocure Announces Results from the Phase 3 Panova-3 Trial of Novocure's Tumor Treating Fields Therapy for Pancreatic Cancer to Be Presented At 2025 ASCO Annual Meeting	May. 31	CI
Novocure Announces Upcoming Investor Events	May. 27	RE
NovoCure's Q1 Loss Narrows, Revenue Rises	Apr. 24	MT
Earnings Flash (NVCR) NOVOCURE Posts Q1 Revenue $155M, vs. FactSet Est of $146.9M	Apr. 24	MT
Earnings Flash (NVCR) NOVOCURE Posts Q1 Loss $-0.31 Per Share, vs. FactSet Est of $-0.46	Apr. 24	MT
NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 24	CI
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of Its Tumor Treating Fields Therapy for Pancreatic Cancer as A Late-Breaking Oral Presentation At the 2025 ASCO Annual Meeting	Apr. 23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Highlights

Filters